UBS increased its price target for Johnson & Johnson stock to $320 from $280 on Tuesday, maintaining a Buy rating for the diversified healthcare company listed on the NYSE under ticker JNJ.
The new target implies a potential 18% upside from the stock’s last close of $271.19, which remains near its 52-week high of $276.47. Over the past year, J&J shares have gained 55.73%, according to the report.
Analyst Michael Yee of UBS did not change the firm’s overall investment thesis on the company but cited an improved outlook as the basis for the upward revision. The adjustment follows a series of similar moves by other brokerages in recent weeks.
Guggenheim raised its target to $287 from $270 while keeping a Buy rating after a site visit with senior management. Raymond James increased its target to $280 from $265, pointing to the FDA approval and limited launch of the Ottava robotic surgery platform. Freedom Capital upgraded J&J from Hold to Buy, lifting its target to $280 from $230, citing strong quarterly results that surpassed consensus and internal forecasts, with TREMFYA revenue exceeding projections alongside outperformance from CAPLYTA and SPRAVATO.
Johnson & Johnson operates across pharmaceuticals, medical devices, and consumer health products, providing a diversified revenue base amid shifting healthcare dynamics.
